Johan Bulten
Overview
Explore the profile of Johan Bulten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
1882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Burg L, Kruitwagen R, de Jong A, Bulten J, Bonestroo T, Kraayenbrink A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612266
The aim was to investigate the incidence of sentinel lymph node (SLN) metastases and the contribution of SLN mapping in presumed low- and intermediate-risk endometrial cancer (EC). A multicenter, prospective...
12.
Rees C, van Vliet H, Siebers A, Bulten J, Huppelschoten A, Westerhuis M, et al.
Am J Obstet Gynecol
. 2022 Dec;
229(1):49.e1-49.e12.
PMID: 36539028
Background: Adenomyosis is a benign gynecologic condition arising from the uterine junctional zone. Recent studies suggest a relationship between adenomyosis and adverse obstetrical outcomes, but evidence remains conflicting. There is...
13.
Vrede S, Kasius J, Bulten J, Teerenstra S, Huvila J, Colas E, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2247372.
PMID: 36525269
Importance: Patients with low-grade (ie, grade 1-2) endometrial cancer (EC) are characterized by their favorable prognosis compared with patients with high-grade (ie, grade 3) EC. With the implementation of molecular...
14.
Zelisse H, van Gent M, de Ridder S, van der Aa M, Van Altena A, Bart J, et al.
Gynecol Obstet Invest
. 2022 Nov;
87(6):389-397.
PMID: 36450222
Objectives: Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For the majority of patients, the 5-year overall survival rate of less than 50% has hardly improved...
15.
Van Bommel M, Pijnenborg J, van der Putten L, Bulten J, Snijders M, Kusters-Vandevelde H, et al.
Int J Gynecol Cancer
. 2022 Nov;
32(12):1568-1575.
PMID: 36384753
Objective: Ovarian cancer is known for its poor prognosis, which is mainly due to the lack of early symptoms and adequate screening options. In this study we evaluated whether mutational...
16.
Ebisch R, Rijstenberg L, Soltani G, van der Horst J, Vedder J, Hermsen M, et al.
Acta Obstet Gynecol Scand
. 2022 Sep;
101(11):1328-1336.
PMID: 36177908
Introduction: Immunostaining with p16 (p16), a tumor-suppressor surrogate protein biomarker for high-risk human papillomavirus (hrHPV) oncogenic activity, may complement standard hematoxylin and eosin (H&E) histology review, and provide more objective...
17.
Steenbeek M, Van Bommel M, Bulten J, Hermens R, IntHout J, de Hullu J
J Clin Oncol
. 2022 Jul;
40(32):3783-3784.
PMID: 35820084
No abstract available.
18.
Hoeijmakers Y, Simons M, Bulten J, Gorris M, Ottevanger P, de Vries I, et al.
Acta Obstet Gynecol Scand
. 2022 Jun;
101(9):1007-1016.
PMID: 35689468
Introduction: Treatment with antibodies directed against programed-cell death ligand 1 (PD-L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD-L1 expression in tumor tissue is commonly...
19.
Andralojc K, Elmelik D, Rasing M, Pater B, Siebers A, Bekkers R, et al.
BMC Med
. 2022 Jun;
20(1):206.
PMID: 35676700
Background: Because most cervical cancers are caused by high-risk human papillomaviruses (hrHPVs), cervical cancer prevention programs increasingly employ hrHPV testing as a primary test. The high sensitivity of HPV tests...
20.
van der Linden M, van Hees C, van Beurden M, Bulten J, van Dorst E, Esajas M, et al.
Am J Obstet Gynecol
. 2022 Apr;
227(2):250.e1-250.e8.
PMID: 35447145
Background: Vulvar Paget disease is an extremely rare skin disorder, which is most common in postmenopausal women. Most vulvar Paget disease cases are noninvasive; however, it may be invasive or...